|
- Aging with Grace
The Nun Study and the Science of Old Age Resource Type: Book
- Alzheimers Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer's disease and Anavexs Phase I clinical program as "Trial
Sources News Release Resource Type: Article Published: 2011 ANAVEX 2-73 has been named 2010s most promising trial drug by the editorial staff at Alzheimers Weekly.
- ANAVEX 2-73 advances Phase I clinical trial for Alzheimer's disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the companys lead candidate for Alzheimers disease. After reviewing all the safety data from the firs
- Anavex adds Dr. Paul Aisen to Scientific Advisory Board
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product pipeline
- Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp., (Anavex) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a potential back-up compound to ANAVEX 2-73 in Alzheime
- Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
Sources News Release Resource Type: Article Published: 2010 Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for its lead compound for the treatment of Alzheimer#s.
- Anavex appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. has announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert. The Scientific Advisory Board works closely with the company to support development of the Anavex product pipeline
- Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support development of the Anavex product
- Anavex comments on new Alzheimer's disease diagnostic guidelines
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimers disease published recently by the National Institute on Aging (NIA) and the Alzheimers Association, which have been updated
- Anavex comments on President Obama's signing of National Alzheimer's Project Act into law
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obamas signing of the National Alzheimers Project Act (NAPA) into law. The passage of this landmark legislation lays the foundation for the first coordinated national
- Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer's disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer
- Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer's disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimers Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofur
- Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimers Association International Conference (AAIC) held in Paris, entitled The novel aminotetrahydrofuran deriva
- Anavex raises $1.575 million
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical trial of ANAVEX 2-73 the companys lead drug candidate
- Anavex rapidly advances ANAVEX 2-73 for Alzheimer's disease, Phase I clinical trial progressing well
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the companys lead drug candidate for Alzheimers disease. This is the third of six potential dose
- Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer's Disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the companys lead compound for Alzheimers disease, has been approved by the German regulatory health authority, BfArM. The
- Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer's Disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzheimers disease. ANAVEX 2-73 is the first of a new
- Anavex strengthens management team with addition of VP, Clinical Development & Medical Affairs
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announced the addition of Dr. Angelos Stergiou to the executive management team in the role of Vice President, Clinical Development & Medical Affairs. Dr. Stergiou has extensive medical and clinical
- Anavex to present at Alzheimers Association International Conference on Alzheimer's Disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. (Anavex) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the companys lead compound for Alzheimers disease (AD) currently in Phase I clinical trials, will be presented in two poster sessions at the 2011 Alzh
- Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
Sources News Release Resource Type: Article Published: 2010 Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare Conference at 4:45 pm ET on Monday, September 13
- Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer's Disease
Sources News Release Resource Type: Article Published: 2011 Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the companys lead compound for Alzheimers disease.
- The Lesson
Resource Type: Article Published: 1997 An educator in a nursing home's essay on Alzheimer's disease.
- Musicophilia
Tales of Music and the Brain Resource Type: Book Published: 2007 Oliver Sacks explores the place music occupies in the brain and how it affects the human condition. In Musicophilia, he examines the power of music through the individaul experiences of patients, musicians, and everyday people.
- Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
Sources News Release Resource Type: Article Published: 2010 Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.
|
AlterLinks
© 2021.
|
|
|
|